NCT05788107View on ClinicalTrials.gov

Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or Lymphoma

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

October 31, 2026

Conditions
Solid Tumor, Adult Lymphoma
Interventions
DRUG

HLX51

anti-OX40 tetravalent agonistic humanized monoclonal antibody

All Listed Sponsors
lead

Shanghai Henlius Biotech

INDUSTRY

NCT05788107 - Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or Lymphoma | Biotech Hunter | Biotech Hunter